Jupiter Neurosciences, Inc. JUNS 深 沪
已收盘 12-12 16:00:00 美东时间
1.12
-0.060
-5.08%
华盛通- 最 高1.2299
- 今 开1.20
- 成交量 4.22万股
- 最 低 1.10
- 昨 收 1.18
- 总市值 3707.64万
- 52周最高 12.8124
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.51
- 委 比 -35.06%
- 总股本 3310.39万
- 历史最高 19.51
- 量 比 0.81
- 振 幅 11.01%
- 历史最低 0.51
- 每 手 1
- 风险率 2.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
Jupiter Neurosciences, Inc. has received FDA clearance to initiate a Phase 2a clinical trial of its JOTROL™ therapy for Parkinson’s disease. The trial aims to evaluate safety, tolerability, and pharmacokinetics of JOTROL, which has shown strong bioavailability and potential neuroprotective benefits. JOTROL’s enhanced delivery system offers over nine times higher bioavailability than traditional resveratrol. The Company expects to begin enrollment...
11-05 13:30
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Jupiter Neurosciences, Inc. (JUNS) has secured up to $20 million in financing from Yorkville Advisors to support its Phase 2 Parkinson's disease trial and expand its Nugevia™ product line. The funding includes a $6 million pre-paid advance and up to $14 million under a Standby Equity Purchase Agreement (SEPA). JUNS plans to use the proceeds for the Phase 2 trial of JOTROL™, its resveratrol delivery platform, and to accelerate marketing and sales ...
10-27 12:30
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
Jupiter Neurosciences announced the addition of Jean Fallacara, a biohacking pioneer and entrepreneur, as the third品牌大使 for Nugevia™, its new consumer longevity supplement line. Nugevia™ leverages the JOTROL™ platform, a patented resveratrol-based delivery system, to enhance bioavailability and support cellular health. With a focus on longevity and resilience, the product line aims to tap into the fast-growing longevity market, projected to reach...
09-15 12:00
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
<p>Jupiter Neurosciences, Inc. announced the launch of its Nugevia™ e-commerce platform and pre-orders for three nutraceutical supplements targeting longevity and wellness. The products, enhanced with the company’s JOTROL™ resveratrol delivery platform, offer improved bioavailability and are designed to support skin health, energy, and cognitive function. The launch supports Jupiter’s dual-path strategy, combining CNS therapeutic development with...
08-26 12:00
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Jupiter Neurosciences, Inc. announced that NBA Hall of Fame Chris Webber has joined as the brand ambassador for its new longevity supplement line, Nugevia™. Webber, known for his championship mindset and dedication to peak performance, aligns with Nugevia’s mission to support longevity, resilience, and elite performance backed by clinical science. Nugevia™, powered by Jupiter’s patented JOTROL™ technology, offers enhanced bioavailability and is d...
08-19 12:12
Jupiter Neurosciences Delays Q2 Financial Report
Jupiter Neurosciences, Inc. ( ($JUNS) ) has released a notification of late fil...
08-15 06:23
Jupiter Neurosciences Launches Nugevia MND To Boost Cognitive Health Using Resveratrol And NovaSOL Curcumin
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective healthJupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,
08-11 20:12
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
Jupiter Neurosciences introduces Nugevia MND, a supplement combining JOTROL™ resveratrol and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health. The product targets aging adults and aims to capitalize on the growing longevity market. Key benefits include improved memory, reduced inflammation, and protection against cognitive decline.
08-11 12:00
Jupiter Neurosciences Highlights JOTROL;
JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor
07-23 20:14
